The first episode of The Biotech Pulse concentrates on the Manufacturing of Complex Bioligics. Forbion General Partner Rogier Rooswinkel speaks to Replimune CEO Philip Astley-Sparke. Philip Astley-Sparke is not only the company's Chief Executive Officer, but he is also its co-founder and has served as a member of its Board since its formation in 2015. Philip was previously the President and CEO of BioVex Inc that developed the first oncolytic therapy which was approved in the U.S. and Europe in 2015. Biovex was acquired by Amgen for up to $1bn in 2011. Tune in to listen to Philip's insight about Contract Development and Manufacturing Organizations (CDMOs) and when to recognize how and when is the right time to go it alone.

The first episode of The Biotech Pulse concentrates on the Manufacturing of Complex Bioligics. Forbion General Partner Rogier Rooswinkel speaks to Replimune CEO Philip Astley-Sparke. Philip Astley-Sparke is not only the company's Chief Executive Officer, but he is also its co-founder and has served as a member of its Board since its formation in 2015. Philip was previously the President and CEO of BioVex Inc that developed the first oncolytic therapy which was approved in the U.S. and Europe in 2015. Biovex was acquired by Amgen for up to $1bn in 2011. Tune in to listen to Philip's insight about Contract Development and Manufacturing Organizations (CDMOs) and when to recognize how and when is the right time to go it alone.

The Biotech Pulse is a Forbion podcast. Forbion is a leading Life Sciences venture capital firm founded in the Netherlands. Forbion helps companies bridge research and development through its team's expertise in drug development and company building. For over 15 years, Forbion has invested in over 100 companies backing exciting therapies that have the potential to impact the future of medicine. The Biotech Pulse is a forum where we speak about all things biotech with diverse stakeholders in the life sciences industry.

The Biotech Pulse is a Forbion podcast. Forbion is a leading Life Sciences venture capital firm founded in the Netherlands. Forbion helps companies bridge research and development through its team's expertise in drug development and company building. For over 15 years, Forbion has invested in over 100 companies backing exciting therapies that have the potential to impact the future of medicine. The Biotech Pulse is a forum where we speak about all things biotech with diverse stakeholders in the life sciences industry.

The Biotech Pulse

Forbion is a leading life sciences venture capital firm founded in The Netherlands, helping companies bridge research and development through our team’s expertise in drug development and company building. Over the course of 15 years we have invested in over 100 companies, backing exciting therapies that that we believe have the potential to impact the future of medicine. “The Biotech Pulse” is a forum where we speak about all things biotech with diverse stakeholders in the life sciences industry.

Forbion is a leading life sciences venture capital firm founded in The Netherlands, helping companies bridge research and development through our team’s expertise in drug development and company building. Over the course of 15 years we have invested in over 100 companies, backing exciting therapies that that we believe have the potential to impact the future of medicine. “The Biotech Pulse” is a forum where we speak about all things biotech with diverse stakeholders in the life sciences industry.

Advertisement